Molecular You Earns Spot on Fast Company’s 2025 Next Big Things in Tech List

Company recognized for its pioneering multi-omic platform that analyzes over 250 biomarkers from a single blood draw, delivering powerful insights for preventive and precision medicine

Vancouver, B.C. – October 14, 2025 – Molecular You, a leader in molecular medicine and preventive health, is proud to announce it has been selected for inclusion in Fast Company’s prestigious “Next Big Things in Tech” list for 2025. The annual list recognizes breakthrough technologies with the potential to create transformative impact across industries and improve lives globally.

Molecular You’s predictive health platform measures over 250 biomarkers across all major systems with a single blood draw to identify health risks at their root cause, often before symptoms appear. The platform uses artificial intelligence (AI) for analysis that provides a comprehensive snapshot of an individual’s health and generates personalized lifestyle recommendations to reduce disease risk.

The platform has already demonstrated remarkable real-world results, including the detection of stage 1 pancreatic cancer in a symptom-free 60-year-old woman, enabling an early diagnosis that led to a life-saving intervention.

“Next Big Things in Tech is both a snapshot of the most interesting tech of the moment and a crystal ball that predicts the next several years,” says Brendan Vaughan, editor-in-chief of Fast Company. “We’re excited to share this list with our readers, and we congratulate the winners for their vision and innovation.”

Molecular You integrates multi-omics data, including proteomics and metabolomics, to create a comprehensive view of each individual’s biology. Measurement of multi-omic biomarkers has been demonstrated (Snyder 2013, Price 2017) to be more effective in detecting disease before symptoms appear. 

“The multi-layered insight that Molecular You provides is built on peer-reviewed science and is particularly powerful for predicting complex conditions like Alzheimer’s, PCOS, and autoimmune diseases, which are correlated to multiple individual biomarkers that are typically measured separately in traditional diagnostics,” said Dr. Rob Fraser, PhD, Chief Scientific Officer, Co-Founder, and President of Molecular You.

Molecular You has recently secured a $5 million Series A led by Voloridge Health to accelerate growth and advance its next-generation multi-omic assay, which will measure over 800 biomarkers, with plans for expansion into cancer diagnostics. The company also announced a strategic partnership with NKCL Bio Group to build a big data platform for early disease detection and personalized care, marking its first commercial deployment in Asia and a launchpad for global expansion.

-##-

About Molecular You

Molecular You measures over 250 biomarkers with a single blood test using advanced proteomics and metabolomics to identify health risks at their root cause. Its AI-powered platform delivers personalized assessments and insights, along with actionable recommendations for over 25 health areas, to support longevity, chronic disease management, and early disease prevention. Both individuals and clinical practices across the United States and Canada are increasingly leveraging Molecular You to maximize personal and patient health outcomes through predictive, preventive, and precision medicine. Learn more: https://www.molecularyou.com/  

About Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Brendan Vaughan. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.

For more information or to view the complete list of honorees, visit here